Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Sees Large Decrease in Short Interest

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) was the target of a large decline in short interest in January. As of January 31st, there was short interest totalling 327,700 shares, a decline of 39.8% from the January 15th total of 544,600 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Hansa Biopharma AB (publ) Price Performance

Shares of Hansa Biopharma AB (publ) stock opened at $3.00 on Friday. Hansa Biopharma AB has a twelve month low of $2.83 and a twelve month high of $3.65. The company has a fifty day moving average price of $2.95 and a 200 day moving average price of $3.08.

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test.